FA Clinical Research
Board
1 director, no change since August 2017Director (not named in the articles)
appointed by deed of 16-08-2017
term without a fixed end
listed in the 2025 annual accounts, filed on 15-06-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “De vennootschap is verbonden door de handelingen van het bestuursorgaan…”deed of 12-02-2024
Mandates through the years
1 name, the dashed line is todayManager (not named in the articles)
Board
Mandates as a list
-
- Manager (not named in the articles), from 11-08-2017 to date
Control
Founder
This company
FA Clinical Research
Equity €247,120
Loss €37,753 in 2025
Capital
- Contribution
- €18,600
- Shares
- 100
- Contribution per share
- €186
- Equity per share
- €2,471 in 2025
- Source
- 2025 annual accounts
Articles of association
deed of 12-02-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 director
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- Op naam, effectenregister van effecten op naam met WVV-vermeldingen
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- Helft overdrager en helft kopers naar evenredigheid aantal bij meer kopers, nietigheid
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Monday of May at 15:00
Shareholders
At incorporation
deed of 16-08-2017 ↗
- 100 shares (100%) · €18,600 in cash
Capital transactions
Capital over time
- 12-02-2024 Converted to unavailable equity
- 16-08-2017 Incorporation · €18,600 · 100 shares